Exploring Innovative Therapies

NeuroSigma, Inc. is developing trigeminal nerve stimulation (TNS) for a variety of disorders, including epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD) Lennox-Gastaut syndrome (LGS) and traumatic brain injury (TBI). NeuroSigma’s unique TNS technology can be delivered via the non-invasive Monarch external trigeminal nerve stimulation (eTNS™) system or the minimally-invasive subcutaneous trigeminal nerve stimulation (sTNS™) system which is currently under development.

The Monarch eTNS system is easy to use and convenient.

This cell phone sized device is now available as adjunctive treatment of epilepsy and depression in the European Union and Canada and as and adjunctive treatment for epilepsy in Australia.

Learn More

CAUTION: In the United States, both eTNS and sTNS are investigational devices and are limited by Federal (or United States) law to investigational use.

Latest News

October 21, 2014 NeuroSigma Receives Notice of Allowance of U.S. Patent Application

October 15, 2014 NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)

August 26, 2014 NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

August 25, 2014 U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

July 22, 2014 Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome

July 9, 2014 NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

July 8, 2014 Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden

June 3, 2014 Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

April 1, 2014 NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

March 28, 2014 NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives

February 25, 2014 David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President

February 11, 2014 Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller

January 27, 2014 Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer

January 21, 2014 External Trigeminal Nerve Stimulation (eTNS) Presentations at the American Epilepsy Society Meeting

Learn More